Françoise Bernaudin (Intercommunal Hospital of Créteil, Créteil, France) joins touchHAEMATOLOGY to discuss the DREPAGREFFE-1 (NCT01340404) and DREPAGREFFE-2 trials (NCT 05053932). DREPAGREFFE-1 was the first prospective study to compare allogeneic stem cell transplantation (alloSCT) with standard-of-care (SoC) for children suffering from sickle cell anemia (SCA), and provided valuable insights into the potential of alloSCT to offer a curative approach compared to conventional treatments. Dr Bernaudin discusses the rationale, trial methology and design and the 10-year follow-up data.
The Late-Breaking Abstract, ‘Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Comparing Allogeneic Stem Cell Transplantation to Standard-Care in Children with Sickle Cell Anemia and History of Abnormal Cerebral Velocities’ (https://ash.confex.com/ash/2024/webprogram/Paper212967.html) was presented at the 66th ASH Annual Meeting & Exposition on 7–10 December 2024 in San Diego, CA, USA.
View more from Francois Bernaudin on Bridging the gap in paediatric sickle cell care: Expanding transplant access globally.
Disclosures: Françoise Bernaudin is a consultant for Bluebirdbio, Vertex, GBT/Pfizer and Terumo; she has received grant/research support from, and is on the Advisory Board for, GBT/Pfizer, and has received honoraria/honorarium from AddMedica and Terumo.
This content has been developed independently by Touch Medical Media for touchHAEMATOLOGY. It is not affiliated with the American Society of Hematology (ASH). Views expressed are the speaker’s own and do not necessarily reflect the views of Touch Medical Media.
Cite: Bernaudin F. DREPAGREFFE-1 trial: Comparing stem cell transplantation and standard-of-care in paediatric sickle cell anaemia. touchHAEMATOLOGY. 22 January, 2025.
